Evidence map›Paper›PMID 36294879›Full record

ArticleJournal of personalized medicine2022

Relatives from Hereditary Breast and Ovarian Cancer and Lynch Syndrome Families Forgoing Genetic Testing: Findings from the Swiss CASCADE Cohort.

Mahesh Sarki, Chang Ming, Monica Aceti, Günther Fink, Souria Aissaoui, Nicole Bürki, Rossella Graffeo, Karl Heinimann, Maria Caiata Zufferey, Christian Monnerat and 5 more

Open access · goldAbstract read
In one paragraph

Article in Journal of personalized medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 16 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Cost-Effectiveness of Lynch Syndrome Identification Strategies in Individuals With Colorectal Cancer and the Impact on At-Risk Relatives.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 10 institutions in 1 country.

Mahesh SarkiDepartment of Clinical Research, University of Basel, 4055 Basel, Switzerland.ORCID 0000-0002-0964-7762
Chang MingDepartment of Clinical Research, University of Basel, 4055 Basel, Switzerland.ORCID 0000-0002-2817-3865
Monica AcetiDepartment of Clinical Research, University of Basel, 4055 Basel, Switzerland.ORCID 0000-0002-9614-4038
Günther FinkSwiss Tropical and Public Health Institute, University of Basel, 4123 Allschwil, Switzerland.
Souria AissaouiBreast Center, Cantonal Hospital Fribourg, 1752 Fribourg, Switzerland.
Nicole BürkiWomen's Clinic, University Hospital Basel, 4031 Basel, Switzerland.ORCID 0000-0002-2625-7619
Rossella GraffeoEOC, Oncology Institute of Southern Switzerland (IOSI), 6500 Bellinzona, Switzerland.
Karl HeinimannInstitute for Medical Genetics and Pathology, University Hospital Basel, 4031 Basel, Switzerland.
Maria Caiata ZuffereyDepartment of Business Economics, Health and Social Care, University of Applied Sciences and Arts of Southern Switzerland, 6928 Manno, Switzerland.ORCID 0000-0003-4197-8913
Christian MonneratDepartment of Medical Oncology, Hospital of Jura, 2800 Delemont, Switzerland.
Manuela RabaglioDepartment of Medical Oncology, Inselspital, Bern University Hospital, 3010 Bern, Switzerland.ORCID 0000-0002-6764-1844
Ursina Zürrer-HärdiDepartment of Medical Oncology, Cantonal Hospital Winterthur, 8400 Winterthur, Switzerland.ORCID 0000-0002-6672-8104
Pierre O ChappuisUnit of Oncogenetics, Division of Oncology, University Hospitals of Geneva, 1205 Geneva, Switzerland.ORCID 0000-0002-3464-9241
Maria C KatapodiDepartment of Clinical Research, University of Basel, 4055 Basel, Switzerland.ORCID 0000-0003-3903-3750
The Cascade Consortium
University of Basel · CHCABI Switzerland · CHFribourg Development Agency · CHInstitute of Oncology Research · CHKantonsspital Winterthur · CHSwiss Tropical and Public Health Institute · CHUniversity Hospital of Basel · CHUniversity Hospital of Bern · CHUniversity Hospital of Geneva · CHUniversity of Applied Sciences and Arts of Southern Switzerland · CH

Funding

The Swiss Cancer League KLS-4294-08-2017The Swiss Cancer Research Foundation KFS-5293-02-2021
6 · The paper itself

Abstract

Cascade genetic testing of relatives from families with pathogenic variants associated with hereditary breast and ovarian cancer (HBOC) or Lynch syndrome (LS) has important implications for cancer prevention. We compared the characteristics of relatives from HBOC or LS families who did not have genetic testing (GT (-) group) with those who had genetic testing (GT (+) group), regardless of the outcome. Self-administered surveys collected cross-sectional data between September 2017 and December 2021 from relatives participating in the CASCADE cohort. We used multivariable logistic regression with LASSO variable selection. Among

Indexed as

barriers to genetic carecascade genetic screeningHBOChealthcare systemrelatives

Identifiers

PMID36294879
PMCPMC9605198
OpenAlexW4306835911

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.